Performance of Indocyanine Green Compared to 99mTc-Nanocolloids for Sentinel Lymph Node Detection in Early Vulvar Cancer.


Journal

Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503

Informations de publication

Date de publication:
26 10 2022
Historique:
received: 05 10 2022
revised: 23 10 2022
accepted: 25 10 2022
entrez: 10 11 2022
pubmed: 11 11 2022
medline: 15 11 2022
Statut: epublish

Résumé

The aim of this study was to evaluate the performance of indocyanine green (ICG) compared to that of the gold standard 99mtechnetium (99mTc-nanocolloids) in detecting sentinel lymph nodes (SLN) in early vulvar cancer. A single-center retrospective cohort study comparing SLN detection by 99mTc-nanocolloids and ICG was performed in patients presenting early vulvar cancer (T1/2), with clinically negative nodes. All SLN showing a radioactive and/or fluorescent signal were resected. The primary endpoints were the sensitivity, positive predictive value (PPV) and false negative (FN) rate of ICG in detecting SLN compared to 99mTc-nanocolloids. Thirty patients were included and 99 SLN were identified in 43 groins. Compared to 99mTc-nanocolloids, ICG had a sensitivity of 80.8% (95% CI [72.6; 88.6%]), a PPV of 96.2% (95% CI [91.8; 100%]) and a FN rate of 19.1% in detecting SLN. Seventeen (17.1%) infiltrated (positive) SLN were identified out of the 99 SLN detected. Compared to 99mTc-nanocolloids, ICG showed a sensitivity of 82.3% (95% CI [73.1; 91.5%]), a PPV of 100% and a FN rate of 17.6% (3/17) in detecting infiltrated SLN. Despite its many advantages, ICG cannot be used as the sole tracer for the detection of SLN in early vulvar cancer and should be employed in conjunction with 99mTc-nanocolloids.

Identifiants

pubmed: 36354698
pii: curroncol29110638
doi: 10.3390/curroncol29110638
pmc: PMC9688937
doi:

Substances chimiques

Indocyanine Green IX6J1063HV

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

8084-8092

Références

Gynecol Oncol. 1995 Jun;57(3):327-34
pubmed: 7774836
J Gynecol Obstet Biol Reprod (Paris). 2015 Dec;44(10):1049-64
pubmed: 26541565
Geburtshilfe Frauenheilkd. 2016 Oct;76(10):1035-1049
pubmed: 27765958
J Natl Cancer Inst. 2015 Jan 24;107(3):
pubmed: 25618900
Nat Rev Clin Oncol. 2013 Sep;10(9):507-18
pubmed: 23881033
Surg Oncol. 2008 Sep;17(3):219-25
pubmed: 18556194
Gynecol Oncol. 2011 Feb;120(2):291-5
pubmed: 21056907
Cancer Causes Control. 2009 Nov;20(9):1779-82
pubmed: 19680749
J Obstet Gynaecol Res. 2022 Mar;48(3):533-540
pubmed: 34962334
Gynecol Oncol. 2020 Dec;159(3):672-680
pubmed: 33041071
Int J Gynecol Cancer. 2017 Oct;27(8):1769-1773
pubmed: 28763369
Br J Cancer. 2014 Jun 10;110(12):2837-46
pubmed: 24867697
Gynecol Oncol. 2008 Nov;111(2):282-8
pubmed: 18804850
Ann Surg Oncol. 2006 Apr;13(4):491-500
pubmed: 16514477
Arch Gynecol Obstet. 2020 Mar;301(3):729-736
pubmed: 32055954
Ann Surg Oncol. 2021 Jun;28(6):3266-3278
pubmed: 33095359
Gynecol Oncol. 2013 Jul;130(1):237-45
pubmed: 23612317
Int J Gynecol Cancer. 2015 Jul;25(6):1086-93
pubmed: 25768079
Minerva Obstet Gynecol. 2021 Apr;73(2):160-165
pubmed: 33306289
Gynecol Oncol. 2013 Dec;131(3):720-5
pubmed: 24051219
Bull Cancer. 2016 Apr;103(4):381-8
pubmed: 26946971
Gynecol Oncol. 2016 Jan;140(1):8-14
pubmed: 26428940
J Clin Oncol. 2008 Feb 20;26(6):828-9
pubmed: 18281651
Int J Gynecol Cancer. 2020 Mar;30(3):383-386
pubmed: 32075896
J Clin Oncol. 2008 Feb 20;26(6):884-9
pubmed: 18281661
Curr Opin Chem Biol. 2003 Oct;7(5):626-34
pubmed: 14580568
Int J Gynecol Cancer. 2017 May;27(4):805-812
pubmed: 28399034
Am J Obstet Gynecol. 2012 Jan;206(1):89.e1-5
pubmed: 21963099
Gynecol Oncol. 2005 Jun;97(3):828-33
pubmed: 15896831
J Surg Oncol. 2011 Sep 1;104(3):323-32
pubmed: 21495033
BJOG. 2013 May;120(6):758-64
pubmed: 23418877
Surg Oncol. 2010 Dec;19(4):e150-4
pubmed: 20833535
Am J Obstet Gynecol. 1987 May;156(5):1159-64
pubmed: 3578430
Bull Cancer. 2019 Apr;106(4):371-378
pubmed: 30898319

Auteurs

Camélia Benmoulay-Rigollot (C)

Department of Gynecology and Obstetrics, University Hospital, 42055 Saint Etienne, France.

Georgia Karpathiou (G)

Department of Pathology, University Hospital, 42023 Saint Etienne, France.

Nathalie Prevot-Bitot (N)

Department of Gynecology and Obstetrics, University Hospital, 42055 Saint Etienne, France.
Department of Nuclear Medicine, University Hospital, 42023 Saint Etienne, France.

Mellie Heinemann (M)

Department of Gynecology, LEON BERARD Center, 69008 Lyon, France.

Beatrice Trombert-Paviot (B)

Department of Gynecology and Obstetrics, University Hospital, 42055 Saint Etienne, France.
INSERM U1059, 42023 Saint Etienne, France.

Tiphaine Barjat (T)

Department of Gynecology and Obstetrics, University Hospital, 42055 Saint Etienne, France.
INSERM U1059, 42023 Saint Etienne, France.

Céline Chauleur (C)

Department of Gynecology and Obstetrics, University Hospital, 42055 Saint Etienne, France.
INSERM U1059, 42023 Saint Etienne, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH